SR
Salveen Richter Roth Capital Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
26
Amgen
AMGN
$150B
| $278.51 | $350 |
26%
upside
| Buy |
8 Feb ‘24
1 year ago |
|
27
Vertex Pharmaceuticals
VRTX
$99.6B
| $388.55 | $559 |
44%
upside
| Buy |
31 Jan ‘24
1 year ago |
|
|
CNTA
28
Centessa Pharmaceuticals
CNTA
$3.04B
| $22.71 | $5 |
78%
downside
| Neutral |
15 Aug ‘23
2 years ago |
|
29
Allogene Therapeutics
ALLO
$246M
| $1.11 | $31 |
2,693%
upside
| Buy |
2 Mar ‘23
2 years ago |
|
30
Autodesk
ADSK
$69B
| $323.80 | $225 |
31%
downside
| Overweight |
24 Feb ‘23
2 years ago |
|
31
Prime Medicine
PRME
$693M
| $3.89 | $22 |
466%
upside
| Neutral |
14 Nov ‘22
2 years ago |
|
32
Precision BioSciences
DTIL
$59.1M
| $5.01 | $30 |
499%
upside
| Neutral |
10 Nov ‘22
2 years ago |
|
33
Recursion Pharmaceuticals
RXRX
$1.98B
| $4.54 | $9 |
98%
upside
| Neutral |
9 Nov ‘22
2 years ago |
|
34
Taysha Gene Therapies
TSHA
$887M
| $3.25 | $3 |
8%
downside
| Neutral |
9 Nov ‘22
2 years ago |
|
35
Sana Biotechnology
SANA
$739M
| $2.91 | $6 |
106%
upside
| Neutral |
3 Nov ‘22
2 years ago |
|
36
Bread Financial
BFH
$2.99B
| $64.07 | $43 |
33%
downside
| Neutral |
28 Oct ‘22
2 years ago |
|
|
CLLS
37
Cellectis
CLLS
$306M
| $3.05 | $2 |
34%
downside
| Sell |
24 May ‘22
3 years ago |
|
38
Atara Biotherapeutics
ATRA
$82.7M
| $11.78 | $100 |
749%
upside
| Sell |
24 May ‘22
3 years ago |
|
39
Passage Bio
PASG
$22.4M
| $7.06 | $600 |
8,399%
upside
| Buy |
4 Mar ‘21
4 years ago |
|
40
PACCAR
PCAR
$51.8B
| $98.66 | $50 |
49%
downside
| Neutral |
19 Mar ‘20
5 years ago |
|
41
Arrowhead Research
ARWR
$3.99B
| $28.89 | $45 |
56%
upside
| Neutral |
17 Mar ‘20
5 years ago |
|